close

Products

1 140 141 142 143
Number of results: 2842
Date Compound Product name Company Disease Action mechanism Type of Information
2011-06-21 human dermal fibroblasts cultured on a bioresorbable polyglactin mesh human dermal fibroblasts cultured on a bioresorbable polyglactin mesh TMC Pharma Services (UK)

epidermolysis bullosa

The medicine is made up of fibroblasts that have been grown in the laboratory to be used as a skin… Granting of the orphan status in the EU
2011-05-06 everolimus Afinitor® Novartis (Switzerland) advanced neuroendocrine tumors (NET) of pancreatic origin mTOR inhibitor. Everolimus is a selective mTOR (mammalian target of rapamycin) inhibitor. mTOR is a key serine-threonine kinase, the activity… Granting of a Market Authorisation in the US
2011-02-07 MOR103 MOR103 Morphosys (Germany) monoclonal antibody. MOR103 is a human monoclonal antibody to GM-CSF (granulocyte macrophage-colony stimulating factor). Granting of a patent
2010-10-01 16-base single-stranded peptide nucleic acid oligonucleotide linked to a 7-amino acid peptide 16-base single-stranded peptide nucleic acid oligonucleotide linked to a 7-amino acid peptide Biogenera (Italy)

medulloblastoma

antisens oligoucleotide.  16-Base single-stranded peptide nucleic acid oligonucleotide linked to a 7-amino acid peptide has been designed to block the gene coding… Granting of the orphan status in the EU
2007-11-29 human recombinant interferon-beta 1a Traumakine® - FP-1201 Faron Pharmaceuticals (Finland)

acute lung injury (ALI) acute respiratory distress syndrome (ARDS)

protein. FP-1201/Traumakine® is a human recombinant interferon-beta 1a. In acute lung injury (ALI) and acute respiratory distress syndrome (ARDS), the predominant patho-physiological result… Granting of a patent
0000-00-00 rasagiline mesylate rasagiline mesylate Takeda Pharmaceutical (Japan) Parkinson’s disease Rasagiline is a monoamine oxidase B (MAO-B) inhibitor. By irreversibly binding to MAO-B, it prevents the breakdown of dopamine in… Submission of an NDA
0000-00-00 eculizumab Soliris® Alexion Europe (Switzerland) myasthenia gravis, refractory generalized myasthenia gravis  in patients who are anti-acetylcholine receptor (AChR) antibody-positive monoclonal antibody. Eculizumab is a recombinant humanized monoclonal IgG2/4 antibody that specifically binds to the complement protein C5, inhibiting its… Granting of a Market Authorisation in Japan
0000-00-00 Plant acquisition
0000-00-00 Compound: Product name: sadasd dsadasdasd asdasdasdas Plant acquisition
0000-00-00 hj hjgh j vhv j Validation of a production plant
0000-00-00 Compound: bestttt asdasdasda asdasdasdas adsasdasdas Plant acquisition
0000-00-00 test test test test test Grant
0000-00-00 humanised IgG4 monoclonal antibody to the human toll-like receptor type 2 OPN-305 Opsona Therapeutics (Ireland) myelodysplastic syndromes monoclonal antibody. OPN-305 is a novel proprietary humanized IgG4 monoclonal antibody (MAb) against Toll-Like Receptor 2 (TLR2), a target within… Granting of the orphan status in the EU
0000-00-00 pppppppppp
0000-00-00
0000-00-00 Compound: bestttt vkh vki Action_mechanism: Company acquisition
0000-00-00 Compound: bestttt Laboratory Indication Action_mechanism:
0000-00-00 knjnlnlnln Product name:lknk nl nl lnl Licensing agreement
0000-00-00 test Establishment of a new subsidiary in the EU
0000-00-00 erenumab Aimovig® Amgen (USA - CA) migraine monoclonal antibody. AMG 334 is a fully human monoclonal antibody under investigation for the prevention of migraine. AMG 334 inhibits… Acceptation for review of a NDA